Therefore, expression levels of ATG7 and LC3 as two key genes in AML patients are targeted in this study.Material and method: This study was performed on 55 de novo AML patients against 17 healthy volunteers, acquired samples from bone marrow (BM) and peripheral blood (PB) sources in different ages and gender. The gene discussed is MAP1LC3A; the disease is acute myeloid leukemia.